{"schema_version":"secwatch.filing_event.v1","accession":"0001615219-25-000125","form_type":"8-K","ticker":"DCOY","cik":"0001615219","company_name":"Decoy Therapeutics Inc.","filed_at":"2025-09-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.488706+00:00","generated_at":"2026-05-17T07:18:29.022313+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Salarius regains Nasdaq bid price compliance; merger with Decoy ongoing","bullets":["Regained compliance with Nasdaq's minimum bid price requirement on Sept. 4, 2025.","Subject to one-year Mandatory Panel Monitor; delisting risk if bid price falls below $1.00 again.","Must also comply with Nasdaq equity standard by Oct. 20, 2025; currently noncompliant.","Planned merger with Decoy Therapeutics to combine into Decoy Therapeutics, led by Decoy's co-founders.","Decoy aims to file IND for pan-coronavirus antiviral within 12 months and advance other pipeline programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001615219-25-000125","json":"https://secwatch.observer/filing/0001615219-25-000125.json","markdown":"https://secwatch.observer/filing/0001615219-25-000125.md","text":"https://secwatch.observer/filing/0001615219-25-000125.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1615219/000161521925000125/0001615219-25-000125-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1615219/000161521925000125/flks-20250904.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T07:18:29.022313+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}